Core Viewpoint - Guangzheng Eye Hospital (002524.SZ) announced that its wholly-owned subsidiary, Shanghai Guangzheng New Vision Eye Hospital Investment Co., Ltd., plans to increase its investment in its wholly-owned subsidiary, Chengdu New Vision Eye Hospital Co., Ltd., by 30 million yuan, raising Chengdu New Vision's registered capital to 40 million yuan. After the capital increase, the company's ownership stake in the subsidiary remains at 100% [1] Group 1 - The investment amount for the capital increase is 30 million yuan [1] - The registered capital of Chengdu New Vision Eye Hospital will be 40 million yuan after the increase [1] - The company maintains a 100% ownership stake in Chengdu New Vision after the capital increase [1]

Core Viewpoint - The company plans to increase the registered capital of its subsidiary Chengdu New Vision Eye Hospital by 30 million yuan, raising it from 10 million yuan to 40 million yuan, using its own funds [1] Group 1: Investment Details - The investment will be made by Shanghai Guangzheng New Vision Eye Hospital Investment Co., Ltd., a wholly-owned subsidiary of the company [1] - After the capital increase, the company will continue to hold 100% equity in Chengdu New Vision, with no change in shareholding ratio [1] - The funding for this capital increase comes from the company's own funds, and it does not constitute a related party transaction or a major asset restructuring [1]

Group 1 - The company Guangzheng Eye Hospital announced the convening of its sixth board meeting on February 12, 2026, to review documents including a proposal for capital increase in its wholly-owned subsidiary [1] - Investors Ge Weidong and Fang Wenyuan have jointly invested 1 billion yuan each in Jianghuai, leading to a significant increase in the company's stock price [1] - Historical analysis indicates that retail investors participating in private placements have experienced both gains and losses [1]

Core Viewpoint - Guangzheng Eye Hospital (002524.SZ) announced that its wholly-owned subsidiary, Shanghai Guangzheng New Vision Eye Hospital Investment Co., Ltd., plans to increase its investment in its wholly-owned subsidiary, Chengdu New Vision Eye Hospital Co., Ltd., by 30 million yuan, raising Chengdu New Vision's registered capital to 40 million yuan. After the capital increase, the company's ownership stake in the subsidiary remains at 100% [1]. Group 1 - Guangzheng Eye Hospital's subsidiary, Shanghai Guangzheng New Vision, is set to invest 30 million yuan in Chengdu New Vision Eye Hospital [1]. - Following the capital increase, the registered capital of Chengdu New Vision will be 40 million yuan [1]. - The company will maintain a 100% ownership stake in Chengdu New Vision after the investment [1].

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2026-006 光正眼科医院集团股份有限公司 关于对全资子公司增资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 光正眼科医院集团股份有限公司（以下简称"公司"）于2026年2月12日召 开第六届董事会第八次会议，审议通过了《关于对全资子公司增资的议案》，现 将具体情况公告如下： 4、注册资本：1,000 万人民币 5、注册地址：四川省成都市成华区经华北路 8 号 6、公司类型：有限责任公司（自然人投资或控股的法人独资） 7、成立日期：2014 年 4 月 23 日 一、增资的基本情况概述 公司全资子公司上海光正新视界眼科医院投资有限公司（以下简称"光正新 视界"）拟对其下属全资子公司成都新视界眼科医院有限公司（以下简称"成都 新视界"）增资 3,000 万元，增资后成都新视界注册资本为 4,000 万元。增资后， 公司对上述下属公司的持股比例仍为 100%。 本次增资属于对全资子公司的投资，不构成关联交易，也不构成《上市公司 重大资产重组管理办法》规定的重大资产重组 ...

表决结果：同意 9 票；反对 0 票；弃权 0 票；回避 0 票。 特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 光正眼科医院集团股份有限公司（以下简称"公司"）于 2026 年 2 月 12 日上午以现场会议与通讯会议相结合的方式在公司会议室召开第六届董事会第 八次会议，会议通知以电子邮件和即时通讯的方式送达。本次会议应出席董事 9 名，实际出席董事 9 名。经全体参会董事一致推举，本次会议由董事长周永麟先 生主持，会议的召集、召开符合《中华人民共和国公司法》《公司章程》等有关 规定。 1、审议通过《关于对全资子公司增资的议案》 根据公司整体战略发展规划及成都新视界眼科医院有限公司（以下简称"成 都新视界"）业务发展需要，进一步提升成都新视界的综合实力，公司决定向成 都新视界增资。本次增资资金将用于成都新视界的日常运营等工作，有助于进一 步夯实其技术壁垒与市场竞争力，提高公司的核心竞争力。 光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2026-005 光正眼科医院集团股份有限公司 关于第六届董事会第八次会 ...

Group 1: Shareholder Pledge and Control - The controlling shareholder, Guangzheng Investment, has had 9.15 million shares frozen, accounting for 7.08% of its holdings and 1.78% of the company's total share capital. The freeze period is from January 30, 2026, to January 29, 2029. The company states this will not lead to a change in control and will not have a substantial impact on operations [2]. Group 2: Financial Performance - The company expects a net profit attributable to shareholders for 2025 to be between -5 million and -3 million yuan, indicating a significant reduction in losses of 97.14% to 98.28% compared to a loss of 175 million yuan in the same period of 2024. This improvement is attributed to lean operations in the medical sector, cost control, and a significant reduction in goodwill impairment [3]. Group 3: Related Party Transactions - The company’s board approved a total of up to 15 million yuan for daily related party transactions with Guangzheng Yanyuan Health Management Co., Ltd. and its subsidiaries for the year 2026 [4]. Group 4: Management Changes - A new senior management team has been appointed, including positions such as Vice President, Chief Financial Officer, and Board Secretary, as of December 28, 2025 [5]. Group 5: Business Development - The company has increased its investment in ophthalmology by acquiring, establishing, and holding stakes in multiple ophthalmology-related companies throughout 2025 [6].

2月6日晚间，光正眼科（002524）发布公告，公司控股股东光正投资915万股被司法冻结，占其所持股份比例为7.08%，占公司总股本比例为1.78%。冻结 起始日为2026年1月30日，冻结到期日为2029年1月29日，冻结申请人为广东省东莞市中级人民法院。 截至公告披露日，光正投资及其一致行动人累计被冻结股份情况与本次冻结情况一致，即累计被冻结股份数量为915.03万股，占其持股总数的7.08%，占 公司总股本的1.78%。 | 股东 | 是否为控股 | 本次冻 | 占其所 | 占公司 | 是否为 | 冻结起 | 冻结 | 冻结申 | 冻结 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 股东或第一 | 结股份 | 持股份 | 总股本 | 限售股 | 始日 | 到期 | 请人 | 原因 | | | 大股东及其 | 数量 | 比例 | 比例(%) | 及限售 | | H | | | | | 一致行动人 | (股) | (%) | | 类型 | | | | | | 光正 | 是 | 9, 150, | 7.08 | 1 ...

Core Viewpoint - The shares of Guangzheng Eye Hospital's controlling shareholder, Guangzheng Investment Co., Ltd., have been judicially frozen, affecting 9.1503 million shares, which is 7.08% of the shares held by the shareholder and 1.78% of the company's total share capital [1] Group 1 - The reason for the share freeze is due to judicial actions, with specific details yet to be confirmed [1] - The share freeze will not lead to a change in the company's control [1] - The company maintains independence from its controlling shareholder in terms of assets, business, and financial matters [1] Group 2 - There will be no substantial impact on the company's production operations or governance as a result of the share freeze [1]

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2026-004 光正眼科医院集团股份有限公司 关于控股股东部分股份冻结的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 光正眼科医院集团股份有限公司（以下简称"公司"）于近日通过查询中国 证券登记结算有限责任公司深圳分公司业务系统，获悉公司控股股东光正投资有 限公司（以下简称"光正投资"）所持有的部分股份被司法冻结的情况。具体情 况如下： 质性影响。 | 股东 | 是否为控股 | 本次冻 | 占其所 | 占公司 | 是否为 | 冻结起 | 冻结 | 冻结申 | 原因 | 名称 | 股东或第一 | 结股份 | 持股份 | 总股本 | 限售股 | 始日 | 到期 | 请人 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 大股东及其 | 数量 | 比例 | 比例（%） | ...